أخبار
GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?
| العنوان: | GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now? |
|---|---|
| المؤلفون: | Muzurovic, Emir, Yumuk, Volkan Demirhan, Rizzo, Manfredi |
| بيانات النشر: | Elsevier Science Inc |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Glucagon-like peptide 1 receptor agonists, Dual glucagon-like peptide 1/gastric inhibitory, peptide receptor agonists, Atherosclerotic cardiovascular disease, Overweight, Obesity |
| الوصف: | [Abstract Not Available] ; Kowa; Mylan; Merck Sharp Dohme; Novo Nordisk; Sanofi; Servier ; clinical trials sponsored by many pharmaceutical companies, including Amgen, AstraZeneca, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche Di-agnostics, Sanofi and Servier. |
| نوع الوثيقة: | other non-article part of journal/newspaper |
| اللغة: | English |
| تدمد: | 1056-8727 1873-460X |
| العلاقة: | Journal of Diabetes and Its Complications; Diğer; https://doi.org/10.1016/j.jdiacomp.2023.108647Test; https://hdl.handle.net/20.500.12831/18939Test; 37; 12; WOS:001112390300001; 2-s2.0-85176437958 |
| DOI: | 10.1016/j.jdiacomp.2023.108647 |
| الإتاحة: | https://doi.org/10.1016/j.jdiacomp.2023.108647Test https://doi.org/20.500.12831/18939Test https://hdl.handle.net/20.500.12831/18939Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.AD6FD411 |
| قاعدة البيانات: | BASE |
| تدمد: | 10568727 1873460X |
|---|---|
| DOI: | 10.1016/j.jdiacomp.2023.108647 |